Pharmaceutical Executive
April 13, 2017
Features
37
4
For Bahija Jallal, chosen this year's Healthcare Businesswomen’s Association Woman of the Year, a passion for translational science has been the central guide in a career rise from cancer researcher to leading a big pharma biotech engine.
April 07, 2017
Features
37
4
Pilot study affirms the value of a standards-based solution for prescription drug traceability-and the need to start now to meet compliance deadlines for the Drug Supply Chain Security Act.
April 06, 2017
Columns
37
4
A review of some of the sales strategy insights on offer at last month’s eyeforpharma Barcelona event.
April 06, 2017
Columns
37
4
Experts debate the practice’s rise up the life sciences agenda.
April 06, 2017
From the Editor
37
4
Two topics in Pharm Exec this month-rare disease research and women in healthcare leadership-share a "common" thread.
April 06, 2017
Features
37
4
Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium-an ambitious global effort focused on accelerating orphan disease diagnosis, and ultimately enabling better treatment options for these underserved patient populations.
April 01, 2017
Columns
37
4
It is hard to resist the sensation that the rhetoric of Shakespeare's Henry V is informing much of the Brexit thinking in Westminster, writes Reflector.
April 01, 2017
Columns
37
4
Jill Wechsler outlines how the new FDA commissioner tasked with curbing regulation, speeding approvals-and collecting more fees to do it.
April 01, 2017
Features
37
4
A conversation with Tommy Fanning, head of biopharma at IDA Ireland, about the country’s growth as a manufacturing powerhouse-and its bid to attract UK-based EMA post-Brexit.
April 01, 2017
Issue PDF
37
4
Click the title above to open the Pharmaceutical Executive April 2017 issue in an interactive PDF format.
March 31, 2017
Special Sponsored Section
37
4
Is the Greek pharmaceuticals and healthcare sector, once a strong bridge between Europe and the East, on the mend after suffering the recent ravages of the global financial crisis and subsequent austerity policies?